drugset / Trial / NCT01004380
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
NaSingle-groupOpen-label
Summary
The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-08
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Farletuzumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | Intravenous |